All treatments
Treatment
Trecondi 1 g powder for solution for infusion clinical trials
2 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma.
This study is looking at a new, stronger chemotherapy treatment for people with high-risk Ewing Sarcoma. It combines medicines like Treosulfan and Melphalan to see how safe and effective they are. The aim is to find better ways to stop this cancer from coming back.
For: Ewing SarcomaItaly - AuthorisedPhase I and Phase II (Integrated)- First administration to humans
A phase I/II open label study to assess safety, feasibility and efficacy of ex vivo expanded, autologous haematopoietic stem and progenitor cell populations that contain CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA in children with autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene.
This study is for children with a rare bone disease called osteopetrosis caused by a specific gene fault. It tests a new genetic cell therapy to see if it's safe, works, and improves their health by correcting the faulty gene in their own cells.
For: Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 geneItaly